mani compani pre-announc select metric revenu and/or
guidanc competitor confer like make earn period
less volatil overal preliminari revenu in-lin better
expect guidanc least met expect bode
well util trend start year seen sizeabl
trade activ extrem view follow healthcar
confer compani strong result expect
strong result left dead signific sell-off
especi stock limit liquid name yet
report clearli littl room error given premium med-tech
valuat go print think esta
could trade major concern
larg due lofti valuat think ew
risk issu earn time around
might work well time around expect abbott
neutral guidanc strong potenti beat throughout
year better libr mitraclip buy
pt may place guidanc current level whether
occur expect revenu come well
mark neutral slid meaning think
bullish report move share back consensu seem low
establish esta buy pt though guidanc could
conserv sure get investor re-interest
buy pt view valuat
compel think guidanc meet consensu could move
share back bit neutral valuat low
solid report occur probabl upsid
downsid poor result lastli buy pt
slump enough think in-lin report might move share
bit beat would strongli reward
see risk see mostli small risk intuit
neutral doesnt much left report guidanc could includ
expens forecast recent year edward ew neutral
model street thv though admit busi
lumpi hard call varian neutral share risen
rapidli like isnt room order miss though
call one neutral model slightli
consensu continu expect turn depress
pleas read import disclosur analyst certif appear appendix
tabl content
rel valuat multipl devic vs
premium indic sub-sectoroveral healthcareequip suppliesprovid serviceshc techpharmabiotechsourc factset
preview forecast revenu adj ep
consensu revenu in-lin adj ep
believ abt earn risk quarter guidanc tightli control
note guid expect solid result diabet
pt recent highlight competit pressur lvad space
like good quarter albeit busi still rel small
currenc seem balanc littl impact currenc
fluctuat despit movement yen late decemb
disproportion expos told penni two beat quarter would
surpris us
arguabl meaning catalyst share compani initi
outlook consensu look report top-lin growth
ep growth recal last quarter call manag
suggest comfort ep growth despit fx variabl though
know consensu fx estim part model organ
revenu growth report minu currenc headwind
expect guid revenu around level revenu guidanc north
boost share materi though expect guidanc
biggest wildcard expect libr mitraclip
could drive growth higher abt share trade ntm ep estim
premium comp group although feel abt growth driver
remain durabl believ growth properli model time
expect near-term multipl expans
turn report segment establish pharma bit soft last quarter
overcom tough comp look color chines market
whether market stabl neuromod await updat
salesforc issu depress recent sult although model
turnaround anytim soon turn diagnost alin growth continu
stellar europ curiou expect ahead
broader test roll-out mid-to-l final expect
continu libr ramp report
segment model establish pharma revenu con
nutrit con diagnost con
devic con
call anticip continu investor focu mitral portfolio
mitraclip cephea tendyn whether may interest
supplement offer repair technolog valv
tricuspid broadli expect cash deploy on-going area
focu given aggress effort late de-lev look commentari
macro landscap particularli expect tax rate well
commentari china diabet portfolio remain hot topic
investor look insight new iter libr ovefral
model chang make chang model
valuat abbott rate neutral share appreci remark
year strong product launch remain posit abt base
busi see pathway drive mid-to-high singl digit growth
although mitraclip still modest portion busi
expect signific ramp label expans said share trade
premium comp group feel share rel valuat
appropri reflect risk vs reward btig provid price target
healthcar polici chang currenc fluctuat healthcar fall
favor fda regulatori agenc product delay failur execut
merger synergi
cagrntm johnsonjnjnot fishertmobuy bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growthy/i growth oper adj aleretot y/i y/i growth y/i growth oper adj btig estim
abbott segment devicesrhythm manag y/i manag y/i growth manag y/i growth y/i y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani adjust stj acquisit optic divestitur
preview forecast revenu adj ep
comparison consensu look revenu ep
given recent concern cvg group paclitaxel toxic drug-
coat balloon competit lvad displac abbott post heartmat
destin therapi label chang heart transplant elig
guidelin sign lvad trim estim
full year last week model consolid organ revenu
growth previous reason believ
util slow feel momentum remain strong key
portfolio tavr diabet pain neuromodul
recent reset think result come least in-lin mayb
tad street top bottom line
last week upgrad share buy cours dismiss
near-term risk specif issu within cvg well advers tax
propos come fruition share materi sinc earli
decemb feel opportun share work
name sourc upsid limit paclitaxel concern eas
less sever impact tax chang better-than-expect perform
non-cvg segment like rtg mitg perhap enthusiasm around low-
risk expans tavr follow march highlight mdt
well-round pipelin product within leadless pacemak ramp spine
includ mazor db therapi new introduct diabet
support growth particularli back
segment anticip continu strength diabet ramp
minim patient guardian connect cgm though
note tougher sequenti comp becom even less favor
respect rtg pain therapi segment continu trend ahead
expect intelli take share player endovascular
stroke technolog remain well posit receiv boost
increment launch riptid aspir cathet portfolio within
coronari structur heart sale still get boost tavr evolut
gain share resolut onyx de grew low rang
quarterli call expect continu focu cvg issu well
detail around specif tax propos expect
provid guidanc upcom call least tax impact
final manag provid pipelin updat recent
healthcar confer anticip littl surpris could
question around china given mdt presenc also anticip
discuss around demand china given mdt sizabl presenc
weak cite multi-n player final cash deploy also
area interest perhap off-set potenti tax issu
select categori forecast heart failur con
cardiac vascular group con minim
invas group legaci covidien con spine
con restor therapi group con
diabet con
model chang make chang model time
valuat rate buy pt base share
trade month ep estim target multipl similar
share histor averag although recent cvg product concern
diminish potenti quarterli beat near-term feel
potenti share reward paclitaxel concern
eas neg tax propos materi and/or enthusiasm
around low-risk expans tavr market addit point
broad-bas pipelin launch support least top-lin
growth spine neurovascular neuromodul leadless pace
diabet risk includ deterior cvg spine market robot
launch materi advers tax propos soft emerg
market margin degrad expans new busi line
competit slippag product timelin chang procedur
reimburs futur devic data fda use cash/m
ntm johnsonjnjnot bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
medtron incom eproduct net y/i good gross total oper oper expens adj oper interest expens non-oper expense/ inc pre-tax incom adj net non-controlling adj net incom adjust ep share total net oper net product product product oper btig estim compani report
medtron revenu ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
preview result alreadi announc procedur growth
forecast provid major stock catalyst way
isrg formal earn report howev commentari procedur
spend competit could impact share stock trade
ntm ep recent multipl still well fast-
grow med-tech peer group price level think investor look
confid commentari procedur system sale potenti upcom
competit intern opportun spend mayb
import control spend allow leverag strong
report preliminari revenu y/i line
forecast beat street estim procedur growth
came estim street
estim compani sale break-out includ instrument
revenu system sale servic revenu align
consensu expect instrument servic sale outperform
system sale pre-announce didnt includ item
await metric model y/i growth oper spend
full year line y/i growth guidanc rang
system ship estim
consensu forecast impli system line
estim ship system oper
guidanc set y/i procedur growth consensu growth
midpoint project procedur volum point
growth rate recent manag commentari note
guidanc rang consid matur procedur alreadi well-
penetr typic provid conserv target metric
rais bar higher compani overdeliv throughout year
view guidanc rang achiev
forecast includ system revenu consensu
instrument revenu consensu servic revenu
con manag previous note compani plan
keep invest employe talent target leverag
oper expens line model y/i growth oper spend
full year updat commentari point toward higher
anticip oper expens may pressur share
beyond result procedur capital-expenditure trend spend expect
addit focu isrg product pipelin expect hear earli
feedback singl port da vinci sp system well ion flexibl
robotic-assist cathet in-develop mix realiti capabl
topic might includ macro environ china joint ventur
japanes adopt last year newli reimburs procedur
model chang wait full earn releas updat
revenu model pre-announce actual chang
forward estim time sinc forecast procedur volum alreadi
fall within guidanc rang
valuat rate neutral continu
out-performance like procedur trade ntm ep
well almost med tech btig provid price target
expect capit spend manipul futur competit
ntm inc ingnnot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
incom etot y/i sale oper interest incom tax non-controlling incom share adjust net adjust adjust net adjust oper expens ep btig estim compani report
enu eda vinci sale rest y/i asp asp realiz inc stock enu y/i vinci instal base da vinci da vinci da vinci da vinci instal y/i seq seq procedur procedures/instal world-wide y/i y/i singl y/i multisit singl blend report stock enu per stock enu instrument enu y/i enue/procedur inc y/i train enu instal base per train enu y/i enu y/i gross profit product product gross profit servic servic btig estim compani report
procedur eu procedur estim gyn dvh y/i y/i multi y/i singl y/i y/i y/i y/i y/i y/i dvp y/i y/i y/i y/i y/i surgeri includ ent cardiac vascular y/i y/i y/i y/i y/i y/i y/i y/i cardiac y/i y/i multi y/i singl y/i y/i surgeri inc y/i gener y/i y/i world-wide y/i seq btig estim compani report
procedur eou procedur estim y/i eu y/i y/i gastric y/i y/i eu y/i y/i y/i world-wide y/i seq btig estim compani report
preview provid preliminari revenu segment januari
revenu in-lin consensu toward higher end
compani guidanc busi line in-lin ahead
forecast biggest beat urology/pelv cardiovascular
compani provid formal guidanc reiter goal
oper revenu growth margin expans
doubl digit ep growth though ep provid would
surpris see ebit margin toward higher end/slightli consensu
expect beat much excit arguabl
way formal earn announc like less catalyst
though bullish commentari tavr potenti earlier lotu launch
use cash may boost share
within product portfolio surprisingli expect interest
tavr acur reportedli strong quarter would interest
center addit eluvia stent look updat convers
decis around mitral boston ownership limit
milliped wonder compani acquisit eye repair
concern drug-coat balloon could question two though
commentari like unchang mention
confer final endoscopi growth bit lighter expect
owe difficult comp curiou hear sustain
high-singl digit growth
model chang make chang model
valuat rate buy pt base share
trade month ep estim target multipl in-lin
market-cap weight basket compani grow revenu ep
similarli view bsx differenti portfolio depend perform
potenti upsid recent support argument
premium multipl also lotu launch happen like
appreci risk includ soft emerg market competit
slippag product timelin chang procedur risk tavr
reimburs futur devic data fda use cash/m
ntm johnsonjnjnot bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/salescagr
boston scientif incom enet y/i product gross research adjust oper incom one-tim interest pre-tax provis incom tax adjust net adjust ep share net oper pre-tax net product product product product tax tax growth adjust adjust pre-tax pre-tax adjust incom tax adjust net adjust tax btig estim compani report
boston scientif revenu edrug-elut y/i y/i heart y/i y/i y/i y/i y/i y/i y/i y/i y/i pelvic y/i y/i btig estim compani report neuromodul reclassifi segment electrophysiolog form rhythm neuro segment begin
preview model revenu consensu
ep street guidanc reiter
healthcar confer last week thu expect major surpris
model ww thv sale thv thv
consensu forecast thv thv
edward quarter alway difficult predict approach
quarter bit caution given possibl increas competit europ
notabl pre-announce point solid acur result
ew valuat seem lofti us note support
mani quarter even miss would expect share
retract mayb sinc expect chang bullish
guidanc given compani analyst day
expect chang guidanc earli year though
manag may ask handicap impact earlier expect
lotu launch recent settlement may also impact
expens spend and/or use cash remov overhang expect
tweak long-term initi and/or timelin reiter
confer expect discuss mitral
pipelin perhap trial design post coapt surpris
mitral guidanc think could focu
model chang chang model time
valuat edward rate neutral feel ew current market
capit price lead market share fulli penetr
matur tavr market year feel share fairli valu
btig provid price target neutral-r stock risk includ
competit patent litig slippag product timelin chang
procedur reimburs futur devic data fda possibl
ntm johnsonjnjnot bdxnot scientificbsxbuy lifesciencesewneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/sal
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us y/i ou y/i heart y/i heart y/i y/i gaap net y/i non-gaap revenu us y/i ou y/i heart y/i heart y/i y/i non-gaap net y/i btig estim compani report
buy pt
preview compani pre-announc result last week
healthcar confer preliminari revenu beat
guidanc doubl beat although
await detail expens expect sequenti improv oper
margin compani gain increment leverag cours
year recal compani pull forward inventori spend last
quarter support growth model ep in-lin
consensu
expect provid guidanc next report
initi direct expect given could catalyst share
posit updat size total address market could also boost
sentiment compani recent provid timelin updat impella
 launch end calendar ecp pend fim outsid
 dont anticip chang cours stemi trial design
area focu earli like continu discuss
fda beyond earn call fairli straightforward
less like stimulu stock given pre-announc
model chang make chang model time
valuat rate buy tweak price target
reset target multipl
compar multipl fallen new target multipl base
month revenu estim mirror current multipl ntm
sale feel compani above-averag revenu growth gross margin
warrant premium multipl peer importantli point multipl
driver potenti upsid street estim includ label expans
stemi popul sizabl treatment pool previous
estim via use diseas area like renal failur acut kidney
injuri geograph reach market risk includ
reimburs slippag product timelin chang procedur patent
litig data fda
ntm inc ingnnot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella y/i inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
preview share rebound trade near record high
preannounc larg revenu beat set guidanc y/i
growth move revenu forecast significantli
higher light out-performance guidanc reflect back
y/i revenu growth make guid y/i growth anticip
seem doabl seem manag tri account
competit lower price result shift toward pharmaci
channel possibl competit intern patient
think meaning portion dxcm volum uplift
repeat believ deeper penetr occur also believ
significantli new doctor geograph expans may
continu forev continu concern
price dont insight potenti time time may
maintain premium price like converg toward libr price
forecast revenu leav gross margin unchang
tweak sg spend percent revenu lower arriv
non-gaap ep estim
earn call anticip discuss verili collabor
develop expect competit pressur product
entrant appetit plan recent convert note
issuanc market dynam relat pharmaci channel payor
model chang updat estim pre-announce
revenu maintain gross margin await full earn releas
also increas revenu outlook meaning maintain
gross margin assumpt despit higher sale level
uncertain metric trend sever move part competit
higher proport patient move pharmaci channel
 pipelin also includ impact recent convert note
issuanc share repurchas well share payment relat
valuat rate neutral believ current multipl
estim ntm ev/sal expens given potenti price
pressur face increas competit valuat seem
bpsebit bpssourc btig estim compani filingsnewold chang
support investor concern competit price
like immedi and/or increas spend expect
meet revenu estim wonder happen price throughout
year risk includ competit increas spend
chang revenu growth rate fda product recal reimburs
price pressur
ntm inc ingnnot sciencesexasbuy medicalwmginot factset data btig estimatespr profitev/salescagrcompanytickerr ptpricemarket cap
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
buy pt pt
preview announc preliminari revenu
includ diagnost breast health medic
aesthet gyn surgic skelet health bulk
beat came strong breast health sale solid perform
diagnost busi aesthet fell short consensu expect
sens investor begun put less emphasi result
divis re-focus overal revenu growth
also expect guidanc formal earn releas late januari
forecast includ revenu ep
adjust ep consensu far estim revenu
gaap ep adj ep target look achiev us
particularli heel beat expect guidanc least
trade ntm price-to-earnings multipl well mid-cap comp
group core busi continu sustain faster pace growth
investor attent turn away aesthet busi would
surpris see trade higher multipl throughout
look beyond quarterli result anticip discuss recent
acquisit new offer core busi market
dynam gyn surgic divis
model chang updat model pre-announce
formal call roll fiscal year estim adjust
revenu ep estim increas breast health outlook
moder diagnost sale forecast build gradual
improv margin
valuat rate buy increas price target
increas valuat multipl roll forward month
adjust ep estim new pt base month
adjust ep estim think use multipl comp group
reflect compani slightli lower revenu growth small increas
valuat multipl account improv investor
sentiment risk includ cyno result adopt chang
reimburs diagnost price slowdown novasur
competit success integr cyno
revenu incom btig estim compani filingsnewold chang
ntm entm eepsrevsdentsplyxraynot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
holog incom million except total y/i sell gener oper interest incom incom tax incom share net calendar loss oper btig estim compani report
holog revenu million except selenia dffm asp y/i selenia tomo asp y/i tomo instal y/i breast imag revenu system y/i breast imag y/i imag y/i breast y/i y/i breast y/i breast revenu y/i breast revenu y/i y/i y/i y/i diagnost y/i y/i y/i y/i gyn surgic y/i skelet y/i y/i y/i y/i aesthet revenu y/i y/i revenu y/i btig estim compani report
preview varian fiscal first quarter model gross oncolog
order y/i vs consensu y/i gross order like still
matter investor stock perform hard predict
frankli confid number vs consensu
unlik mani med-tech peer share recov
tumultu month believ varian busi perform well
share mid-to-high think expect rel high
go quarter believ healthi gross order beat perhap
slightli higher need move share higher
share help part posit updat effort mitig
impact tariff halcyon made china recent receiv exclus
us tariff look addit detail resolut may
store
model call revenu y/i street
estim y/i non-gaap ep line model vs
street forecast includ proton revenu near
street estim seem var book-to-instal time come
recent quarter revenu convers impress
possibl conserv revenu convers
continu strong consensu number like okay
full fiscal year street model within guidanc
estim gross oncolog order y/i total revenu
y/i non-gaap ep street forecast
gross oncolog order y/i total revenu
y/i non-gaap ep
varian manag team like discuss integr recent
acquisit product pipelin first introduc astro medic
meet octob opportun order chines licens
tariff negoti macro environ evolut toward
broader cancer-fight compani compani may also ask
think mri imag space
model chang add estim model
valuat varian rate neutral feel current valuat
ntm ep estim expens varian six-point premium
multipl compani similar growth btig assign price target
neutral-r stock risk includ halcyon adopt chang oper
margin capit spend slowdown hospit govern new
gross incom ebit btig estim compani filingsnewold chang
competit healthcar multipl gener trade lumpi quarterli
ntm johnsonjnjnot bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discont op non-control non- dilut share net ex select calendar loss net product product product oper ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
preview week confer compani
pre-announc revenu complet test
street-high estim present
manag also suggest comfort consensu revenu
formal guidanc provid februari earn call
consist past practic expect provid initi
conserv rang start could consensu
strong variabl expect around flu impact
primari care visit although cdc number seem milder thu far year
incid seem pick final investor also watch
commentari around rate contribut
think recent decis expand market agreement includ ob-
gyn cushion number believ exact quit pleas
earli effort expect bullish tone suggest could
upsid number guidanc set higher drive posit
addit ob-gyn channel provid posit
wonder chang expect look updat progress
recent salesforc hire plan creat salesforc sole
dedic gi channel respect label expans manag
note plan toward improv fals posit rate exist cologuard
cologuard well work age group final
manag recent provid timelin upcom trial liver cancer
well new initi develop pan-canc test cancer build
exist relationship mayo
could question two competit blood product especi
expect data upcom confer thu far test sensit
remain inferior cologuard yet see convinc data
earli stage cancer pre-cancer polyp activ work
improv blood test last week ceo comment
stage sensit better anyth seen
model chang chang model time model
revenu consensu wonder may
proven low execut especi new channel
valuat rate buy pt base dcf
assum discount rate termin ev/ebitda multipl
risk includ cologuard adopt execut co-promot
agreement unsuccess expans younger patient increas spend
competit data new product guidelin chang chang
discuss chang obamacar chang reimburs
addit delay poor data lung test need
capit difficulti hire salespeopl creat strong advertis high-
multipl healthcar stock fall favor
exact scienc incom million usd except per-shar etot profit relat y/i profit research gener sale interest expens incom incom incom ep share analysi revenu good profit product revenu ex net incom tax incom net incom btig estim compani report
exact scienc revenu million enumb order sequenti new physician adopt assumptionsnew physician order tests/new complianc test new reorder rate assumptionsreord order tests/reord complianc test reorder cologuard test growth tests/ord testsscreen opportun penetr rate annual volum tradit volum medicar volum volum tradit medicar reimburs reimburs medicar reimburs medicar laboratori servic accrual revenu revenue-per-test ex- btig estim compani report
buy pt pt
preview first time rememb rel new
cfo helm report preliminari revenu ep non-
gaap ep around competitor confer earli januari
report product revenu total revenu
expect exceed ep non- ep
result line slightli forecast consensu estim
compani also publish guidanc target total
revenu ep non- ep slightli
consensu forecast revenu non-gaap ep
move estim higher outlook assum strong
growth board/monitor shipment continu price remain rel stabl
use tax rate without benefit addit commentari
revis forecast line guidanc total sale
ep non-gaap ep consensu forecast total revenu
ep non- ep given masi recent tendenc
offer achiev guidanc beat feel outlook may move higher
throughout year expect investor keep discuss potenti
higher ep growth royalti revenu fulli model
effort keep move higher help share
one top pick continu believ sever
toward guidanc on-going catalyst philip phg rate
partnership meaning contribut growth newer
measur multi-year contract potenti futur oem
partnership interest opioid-rel home monitor
intern adopt trend togeth lead us see bright futur
howev share move higher see littl could
serv major catalyst around formal earn report anticip
commentari may includ pipelin progress updat philip
partnership uptak rainbow newer measur hospit
model chang pre-announce result roughli line
model await full earn releas updat actual quarter
howev increas revenu estim per recent guidanc
model total revenu ep non-
valuat rate buy increas price target
base multipl mo non-gaap ep
forecast increas result rais forward estim believ
compani strong growth profil philip partnership fast cadenc
product innov warrant valuat multipl comp group
compar compani fast-grow product revenu view
reason comp tabl includ profit med-tech compani
similar revenu ep growth rate risk includ price hospit
admiss volum hb adopt margin advers impact relationship
philip competit
incom btig estim compani file adj ep includ adjust due fxnewold changentm medicalgmedneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
masimo incom eproduct y/i y/i y/i good gross litig award defens costs- total oper oper incom non-oper pre-tax incom tax non-control interest net share total non- adjustments- non- net adjust ep marginsgross gross net total total total oper ep ep ep ex royalti btig estim compani file adj ep includ adjust due fx
masimo revenu eglob instal base instal base new unit y/i unit annual retir instal base y/i new unit rainbow monitor total instal busi averag instal base averag y/i sensor asp estimate sensor respiratori set y/i total product busi asp y/i rainbow y/i rainbow average rb instal base average y/i rainbow sensor asp estimate sensor y/i total product sphb y/i product y/i y/i net y/i btig estim compani report
preview model revenu adj ep
consensu revenu adj ep model constant
currenc growth exclud tandem bring full year
estim manag expect estim
assum step-down growth cycl sentiva launch
ramp hlm sale enter quarter caution particularli around
cardiac surgeri result given introduct variabl last quarter
includ percev sale transit delay tandemlif hire
convers confid neuromodul estim quarter
unsur success off-set volatil cardiac surgeri number
share fallen follow less favour propos
depress feel rel valuat fair risk
underli busi uncertainti ahead final vn decis
expect februari would recommend own share ahead
expect posit chang said announc trial
regardless long term likelihood reimburs think share
could trade bit addit also expect provid initi
outlook consensu look revenu growth
think reason back continu momentum within
neuromodul cardiopulmonari replac tailwind ep growth
howev bit tougher call expens come higher expect
could trend even higher requir rigor trial
multipl depress also heard physician caisson
trial may hold true could either decreas trial expens
increas expens fix issu investor confer
novemb manag suggest sg could level
percentag sale believ stabl opex margin model
reflect
cardiopulmonari hlm sale continu benefit upgrad
replac exist devic competit gain turn
heart valv management note previous key chang leadership may
take quarter two play regard neuromod anticip on-going
sentiva adopt neuromod unit ou momentum
buoy sentiva ramp europ well busi model
chang japan
estim segment model cardiopulmonari sale con
heart valv sale con neuromod sale
call look updat caisson interlud ce mark
trial begun enrol curiou livn
appetit increment invest outsid highlif caisson possibl
transsept repair space depress engag activ
discuss regard trial design respons vs remiss endpoint trial
size possibl manag may comment expect
discuss long-term initi includ heart failur hf sleep
model chang chang model time
valuat rate neutral price-to-earnings basi share trade
mani livn peer large-cap mid-cap grow revenu similar
place flip side share also trade smid cap name
feel grow faster long-term use target multipl line similar
smid cap grower see fair valu think immedi
accret growth market could serv catalyst stock
depress await final decis februari coverag
evid requir may come continu uncertainti btig
provid price target neutral-r stock risk includ beat guidanc
competit issu fda leadership transit capit deploy
 new product trials/develop unsuccess effort toward
medicar coverag vn treatment-resist depress
ntm capjohnson johnsonjnjnot bdxnot scientificbsxbuy cap capresmedrmdnot medicalwmginot cap factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
-- -- -- -- -- -- restat divestitur -- -- -- -- -- -- -- non-gaap incom good sold oper incom continu incom continu minor tax expens net share oper pre-tax net net net net oper calcul effect tax calcul effect tax btig estim compani reportsfor quarter tax-effect earn use tax rate deriv ep comparison purpos
consolid million machin includ report cc report cc system report cc report cc report cc heart report cc heart valv includ sutureless report cc report cc report cc sorin btig estim compani note sub-seg within cardiopulmonari heart valv cardiac rhythm repres btig estim actual result attempt estim line item base histor provid sorin prior merger go-forward basi compani disclosur
consolid revenu million epilepsi marketestim new lead revenu gener revenu revenu new need implant assum yr receiv gener revenu lead gener neuromodul epilepsi marketestim new y/i lead revenu gener revenu revenu new need implant assum yr receiv gener revenu y/i ou lead ou gener ou neuromodul cc revenu legaci btig estim compani report
preview fourth quarter forecast total revenu
non-gaap ep consensu non-gaap ep
estim toward top end total revenu guidanc
rang expect meet come ahead
consensu guidanc re-affirmed earli januari
variou busi line forecast us omnipod sale
intern omnipod sale drug deliveri revenu
consensu close estim forecast us omnipod
sale intern omnipod sale drug deliveri
share weak recent week havent found good
fundament reason stock trade point fast-
grow med-tech comp group cant explain discount also
find lot investor appetit time think beat would move
anticip offer guidanc full year
forecast call full year total revenu includ
us omnipod sale intern omnipod sale drug
deliveri sale model gross margin full year consensu
estim includ total revenu includ us
omnipod sale intern omnipod sale drug
deliveri sale gross margin improv impress recent
quarter new manufactur facil expect hit gross margin
think revenu guidanc bracket consensu like though
note first report incom cfo could choos
conserv also look sale guidanc forecast call
total revenu consensu look
manag like discuss broader roll-out dash platform
us omnipod horizon pipelin product direct sale europ shift
toward pharmaci channel us detail ypsome
model chang make chang model time
valuat insulet rate neutral trade ntm
revenu forecast btig provid price target neutral-r stock
risk includ disrupt intern revenu instal patient
base increas competit potenti prefer partnership
major insur group lack visibl next drug deliveri
product
ntm inc ingnnot diabetestndmnot medicalwmginot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
incom statement adjust nd etot revenu y/i growth adjust neighborhood good oper expens tax expens net incom share net incom adjustments- gaap net incom gaap ep growth y/ymarginsgross incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens quarterli result growth rate adjust neighborhood divestituresourc btig estim compani report
revenu etot revenu omnipod y/i omnipod y/i deliveri y/i revenu exclud neighborhood y/i growth adjust neighborhood revenu omnipod revenu breakdownbegin instal new patient start patient y/i patient attrit instal instal base average es order per re-ord annual new user quarterli annual asp new patient revenu new user total omnipod y/i productivity/rep omnipod revenu breakdownbegin instal new patient patient y/i patient attrit instal instal base average es order per re-ord quarterli annual asp new user quarterli annual asp new patient new user total omnipod y/i deliveri revenuesymphoni health data forecast neulasta syring neulsasta onpro total neulasta y/i estim neulasta sale attribut onpro neulasta sale attribut onpro total neulasta onpro end-us neulasta onpro impli neulasta onpro total neulasta onpro total neulasta onpro revenu total neulasta onpro drug total report drug deliveri sourc btig estim compani report symphoni health solut symphoni health symphoni health b/c btig estim report drug deliveri revenu /f btig estim
preview model revenu lp
consensu lp model impli
guidanc year see reason growth rate
deceler particularli larger bolu rep on-board becom
product note said take month rep
becom product per comment healthcar confer
headcount includ field rep end stabl overal
feel irtc model remain competit well-posit anoth beat
mani high-valu name pinpoint one near-
term catalyst would justifi multipl expans although
market penetr still low doubl digit larger number becom
tougher grow encourag expand market
opportun area like silent af may take good outcom
seen thu far impact clinic practic
expect provid initi guidanc upcom earn call
right consensu look growth base
compani said last week confer headcount ramp
growth rate appear reason consensu headcount
estim toward lower end overal continu like
stori struggl share rel ev-to-sal valuat ntm
revenu estim particularli face grow competit tougher
call would interest impact construct data seen
patient popul silent af cryptogen stroke whether
impact convers thought leaders/ physician although
three-year endpoint mstop schedul come
earliest would interest studi may publish
competit landscap alway hot topic sens consider
lead privat player like bardydx privat even
rate continu make inroad lastli found recent stanford
find deep learn algorithm diagnost accur
cardiologist broad rang arrhythmia interest although
work need clinic commun data set add bodi
evid buoy zio product
model chang make chang model time
valuat irhythm corpor rate neutral remain posit
base busi worri competit long-term see irtc
current ntm ev-to-sal valuat vs fast-grow peer
group fair btig provid price target neutral-r stock
risk includ competit ip protect new market delay reach
profit medicar commerci reimburs abil recruit/retain
salespeopl unsuccess salesforc execut broad healthcar sector
ntm inc ingnnot inc beatnot factset data btig estim price ptpricemarket cap bp/e ex-amortev/salescagr
-- -- -- -- -- -- -- -- restat -- -- -- -- -- -- -- -- -irhythm incom million usd except per-shar research sale income/ loss incom share analysi revenu good net incom tax margin incom net incom btig estim compani report
-- -- -- -- -- -- -- -- restat -- -- -- -- -- -- -- -- -irhythm revenu million zio xt growth growth restat y/i growth annual rep fte revenue-per-ft chang chang chang zio mct procedur rate penetr stream mix given client mix mix direct direct btig estim compani report
preview januari pre-announc revenu
consensu estim addit compani also provid initi
revenu outlook impli growth
consensu manag provid product breakdown
indic open surgeri atriclip growth solid notabl
seem anoth atriclip implant sequenti
meaning quarterli ramp forecast manag
continu target posit adj ebitda goal slip due part
higher legal expens associ doj investig
although remain well-posit drive beat especi atriclip
continu exceed think next catalyst share closer
converg data read-out share alreadi trade ntm sale
feel fair consid revenu growth
call look updat train program set
ramp also anticip discuss product iter
pipelin includ cryo nerv block product schedul launch earli
final interest ramp china new distribut
agreement baheal privat gain traction
model chang make chang model time
evalu estim learn segment expect
earn call
valuat rate neutral ev-to-sal basi share
trade next twelv month estim though expect investor
interest heighten near data encourag
consist open surgeri result feel share fairli valu
consid compani revenu growth absenc materi
catalyst trial data releas await better entri point
share perhap ahead converg data btig provid price
target neutral-r stock risk includ trial data success physician
train surgic procedur salesforc product open-heart surgeri
volum fda volatil ou result share shift away surgic
ablat procedur litig
ntm inc ingnnot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
atricur incom research gener expens incom pre-tax incom tax net incom dilut ep share net incom tax expens incom amort compens adjust ebitda margin y/i chang analysi good research gener net incom tax btig estim compani report
statesest open-heart procedur open-heart ablat ablat mi procedur mi asp invas ablat atriclip procedur atriclip asp ablat tool unit open-heart procedur ou open-heart ablat ablat mi procedur ou mi ablat atriclip procedur ou atriclip ablat atriclip tool btig estim compani provid dollar revenu per segment procedur price detail present model estim base compani commentari
preview announc strong preliminari revenu earlier month
beat consensu come ahead
street-high estim compani expect grow revenu
well pre-announce way share
move meaning higher respons anticip major stock
movement around formal earn report
think out-performance driven number factor
includ continu roll-out flexitouch expand salesforc
new feder suppli schedul award septemb
look ahead think manag may offer specif
revenu rang year increas revenu outlook
growth guidanc model revenu year
maintain project sale rep headcount increas peopl
adjust ep consensu forecast revenu adj
ep keep mind tcmd histori repeat beat rais
anticip revenu guidanc rang could bracket consensu
move higher throughout year addit result guidanc
manag commentari may includ discuss flexitouch
head neck product va channel regulatori outlook product
model chang updat model pre-announce
guidanc model revenu growth
revenu growth sinc assum higher rep product
addit rep headcount top expans weve alreadi model
drive sale growth adjust gross margin oper expens
percentag revenu time await detail
compani margin consid chang forecast
spend rais revenu forecast drive three-cent uplift adj ep
four-cent increas adj ep
valuat rate neutral
current trade ntm revenu multipl small-cap medic
suppli comp group believ premium multipl appropri given
tcmd expir patent potenti competit price pressur
beat rais great valuat seem least full us
risk includ potenti increment share dilut lcd decis
competit expir patent technolog advanc reduc burden
lymphedema salesforc buildout market size estim vari doctor
opinion pcd stand-alon treatment
revenu net ep bpsebit bpssourc btig estim compani filingsnewoldvari
ntm inc ingnnot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/salescagr
incom good gross total oper expens incom pre-tax incom tax adj net incom adj net incom loss ep dilut share net incom adjustments- net incom adj adj ebitda profit incom tax net oper btig estim
revenu revenu y/i revenu y/i revenu y/i revenu y/i forc histor quarterli headcount estim additionsregion headcountregion end revenue/rep quarter revenu end y/i btig estim compani sec file
preview januari compani pre-announc revenu
street-low forecast high level compani also
provid key assumpt expect global commerci
placement vs base end recal
compani complet rework busi model move away
evaluation-to-capit sale model reagent model compani assum
placement sold month lag instrument becom
fulli activ run test outlook straightforward wed
like lend variabl consensu estim frankli clear
us exactli outlook specifi weve heard
investor feel stock remain show stori continu
posit encourag placement addit impli
new sale pitch must work alway cautiou
commit hospit long-run make invest although
share becom attract depress level
idea model compani futur revenu thu see invest
guess
jp morgan healthcar confer compani provid high-level
overview market highlight goal captur
market materi ramp record
guid type lack credibl would much prefer
manag outlin guidanc expect
revenu back half meaning potenti achiev
guidanc near-term would go long way help investor sentiment
view especi miss manag hope entri
china increas penetr europ potenti
payment cushion number call manag may
recap strategi dont expect chang timelin offer
model chang updat model pre-announc
well placement expect offer manag
admittedli work new metric go forward requir
us work differ set assumpt prior model take
best guess assumpt capit mix number activ
valuat rate neutral valuat dcf-
base use discount rate given string quarterli miss
uncertainti around success new sale model see risk
revenu loss marginnmnmnmnmnmnmnmnmnmsourc btig estim compani filingsnewoldchang
achiev estim feel take quarter
meeting/b estim establish investor confid btig
provid price target neutral-r stock risk includ compani
acquir meet estim lengthen adopt cycl lrti data
build salesforc ou expans competit chang
fda regul need capit retract healthcar stock
valuat hospit spend slowdown
incom million except ep elicens y/i oper expens incom tax incom share incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens incom nmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet oper loss btig estim compani report
placement/revenu eu capit equipmentinstru contract evalu cumul begin quarterli quarterli quarterli contract evalu cumul end instrument quarter addit reagent instrument asp instrument sold contract instrument cumul new way forecast capit instrument sold instrument revenu per day per activ per per activ y/i consum revenu revenu equipmentinstru contract evalu cumul begin quarterli quarterli quarterli contract evalu cumul end instrument quarter addit reagent instrument asp instrument sold contract instrument cumul new way forecast capit instrument sold instrument revenu per day per activ per per activ y/i consum revenu ou revenu equipmentact instrument quarter addit revenu per day per activ per activ consum revenu product revenu btig estim compani report
preview sinc report preliminari revenu gave
revenu forecast anticip much new inform around
consensu expect expect discuss earn call
around health core busi detail sinuva roll-out
manag expect ramp limit fashion throughout year
unclear us whether offer sinuva-specif revenu guidanc
maintain estim model guidanc
total revenu sinuva sale lp consensu
forecast total revenu lp
accord recent public manag commentari seem patient
access issu prior author approv eas bit think
hiccup may continu plagu sinuva next coupl quarter
core propel franchis new sale rep place hope learn
whether busi get back track addit oper
revenu updat look updat compani plan pursu
product-specif code use
model chang make chang model time
plan updat pre-announce full earn releas
valuat intersect ent rate neutral intersect primarili valu
sale growth trade ntm ev/sal estim
comp group feel fair light lower revenu
growth complex around sinuva launch reimburs
interest point one could say street larg remov
valu sinuva valu fairli core sale btig
provid price target neutral-r stock risk includ product access
commerci payor pushback futur competit advers event relat
product
ntm medicalwmginot factset data btig estimatespr ptprice market cap bp/e ex-amortev/salescagr
incom etot y/i sale oper incom incom tax expens incom share oper expens btig estim compani report
revenu etot propel/contour y/i propel/contour y/i y/i propel/contour q/q propel/contour q/q q/q per unit sold per unit sold per per unit sold sale rep etot distribut rep rep rep month rep btig estim compani report
buy pt tbd
preview alreadi report revenu mridian system
one upgrad slightli ahead consensuss estim
order quarter total system forecast
either match come near consensu
guidanc provid earn call
forecast revenu consensu model
gross order full year like consensu continu expect
metric lumpi hard predict quarterli basi
earn call expect discuss order funnel health
backlog effort improv servic train capabl progress
pancreat trial custom interest adapt plan cash burn note
compani recent file mix shelf
elekta ekta-b st rate enter us market
mr-linac wed like updat sale rep sell competit
whether custom decision-mak process/tim chang
new entrant impact funnel
model chang make meaning chang estim
time plan updat pre-announce full earn
releas account recent term loan agreement use
repay prior term loan reduc quarterli interest payment slightli go
order order marginnmnmnmnmnmnmnmnmnmsourc btig estim compani filingsnewold chang
valuat rate buy price target base
month revenu estim multipl vray current ntm
revenu multipl risk includ competit order volum abil convert
order revenu system fall backlog mri rt adopt long-term
clinic data potenti dilut product delay high oper expens
ntm inc ingnnot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
incom product servic total y/i other- total cost gross sell gener total oper incom loss incom pre-tax incom incom taxes- net incom non-controlling net incom loss share marginsgross net oper expensenanananananananananananananananananananaep growthnanananananananananananananananananananasourc btig estim compani report
revenu egross y/i y/i y/i y/i y/i growthnanananananananananananananananananananatot y/i y/i unit product servic gmnanananananananananananananananananananatot total btig estim compani report
preview dont expect formal earn releas major catalyst
share compani pre-announce preliminari revenu
line consensu report five senhanc system sale includ one us
system quarter
may get peek system sale sinc manag histor
given report system sale alreadi complet quarter
look three system sale one us two rest world
progress report track ahead could help share move higher
continu believ book us senhanc sale import
share expect manag discuss us sale funnel surgeon
feedback demo- system procedur perform
senhanc current custom key topic includ recent
regulatori win taiwanes fda approv senhanc instrument
fda clearanc ultrason system anticip impact
adopt procedur volum
model chang make chang model time plan
updat pre-announce full earn releas
valuat rate neutral valuat base dcf
btig provid price target neutral-r stock risk includ
servic need wrist instrument larger competitor litig
economi pressur capit spend reimburs need
incom etot revenu y/i good intang chang fair valu cont oper incom interest incom tax expens net incom share net incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens btig estim compani report
revenu esenh salesu senhanc sale revenu row revenu total senhanc revenu senhanc instal baseu instal ins- senhanc instrument/stock revenuetot target market senhanc market procedur procedur total row target market senhanc row market row procedur row procedur senhanc world-wide procedur instrument asp total instrument revenu senhanc requir stock us- senhanc requir stock total senhanc requir stock asp total stock revenu total senhanc instrument stock revenu senhanc servic train revenu instal base per system servic train revenu total senhanc revenu revenu btig estim compani report
preview model revenu consensu forecast
find unlik consensu beat estim
anticip step-up sequenti magnitud quarterli
improv within estim sizeabl increas seen
even feel q/q trend support out-performance
brazil scandinavian countri on-going shift direct busi
model recogn lumpi distributor order still
expect come
manag may provid initi revenu outlook along
result model revenu street impli growth
think growth rate achiev continu salesforc expans
entri new geographi penetr brazil market
share captur allergan rate exit textur market
europ light neg headlin around breast implant cancer
concern icij report etc possibl manag may choos
guid conserv start would expect beat cours
year
call look color around dynam brazil close
revenu watch commentari regard enrol
trend pivot trial think investor could react posit
enrol trend faster expect and/or strong physician demand
discuss
model chang chang model
valuat establish lab rate buy believ establish
lab share deserv multipl similar fast-grow med-tech compani
above-averag revenu growth attract gross margin less risk
around reimburs opinion target multipl reason
appli month revenu estim yield price
target add base dcf potenti revenu get
properti fda unsatisfactori salesforc effort contract healthcar
multipl account error deterior geopolit condit
comp tabl fast-grow med-tech aesthet compani
ntm deviceabiomedabmdbuy inc ingnnot averag excl ntm ev-sal cuteracutrnot ntm ev-sal labsestabuy factset data btig estimatespr price ex-amortev/salesp/ ex-amortev/salescagrcompanytickerr ptpricemarket cap bp/e ex-amortcompanytickerr ptpricemarket cap bev/salescagr
establish lab incom y/i full year good gener expens includ fv deriv expens /incom incom incom per share analysisgross gener analysisgross gener btig
establish lab revenu ezon north west south report fx organ report fx organ report fx organ report fx organ report fx organ report fx organ zone report fx organ zone report fx changey/i organ growthzon southeastern europ asia report fx organ report fx organ report fx organ report fx organ zone report fx organ zone report fx changey/i organ growthsourc btig
establish lab revenu ezon south report fx organ report fx organ report fx organ zone report fx organ growthnmnmnmnmtot zone report fx changey/i organ growthzon central america smaller south america report fx organ report fx organ zone report fx organ zone report fx changey/i organ growthou implant report report state americaunit organ growthconsolid report fx changey/i organ growthsourc btig
preview follow earn call laid rough
approxim us eversens roll-out believ consensu model
reset achiev level forecast revenu lp
compani report line consensu expect
lp expect least meet consensu
look toward model revenu lp vs
consensu expect think compani like
offer revenu rang new cfo place unsur
expect guidanc case manag alreadi point
target least us eversens patient year end believ
guidanc rang like match metric
share near one-year low expect set see
achiev level first half view today price level
compel entri point alway potenti new medic
technolog like eversens run hiccup expect sale ramp
meaning back half
though payor win earli week eversens us
launch compani press releas addit payor win recent
week heard hand investor concern larg
payor polici coverag updat categor eversens investig
uncommon new medic technolog expect
larg payor eventu make posit coverag decis aetna aet
rate octob difficult predict time continu
see reimburs major factor earli quarter eversens
launch acceler addit larg insur win would posit
addit commentari sale salesforc product insur
coverag hope hear addit discuss patient physician
feedback includ eas implant explant procedur
learn curv provid payment implant explant key
topic includ negoti roch rhhbi rate though
may hear updat earn call given januari
extend deadlin latest supplement file recent start
us eversens xl implant trial develop system
model chang make chang model time
valuat senseon rate buy price target base
month revenu estim risk includ commerci launch time
payor coverag competit reimburs roch rhhbi rate
distribut agreement partnership futur data
ntm inc ingnnot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
senseon incom revenue- gross sell research gener total oper expens incom pre-tax incom tax benefit adj net incom ep share profit incom tax net oper btig estim
preview execut revenu gross order last quarter
investor like look continu strength revenu
meet consensu gross order give posit comment global order
accuray forecast gross order net order
age-out guidanc estim total
revenu quarter includ product revenu servic
revenu lp estim bit consensu
forecast gross order net order total
revenu product revenu servic revenu well
model total revenu match consensu
top half guidanc rang becom
consist recent quarter revenu result see
consensu outlook doabl model call gross order
y/i consensu y/i meet
consensu number gross order like remain import share
perform see metric achiev home run given
lumpi natur order
sinc order remain import difficult metric predict
precis continu believ rel small capit equip compani
like higher-than-averag risk volatil around earn
report still see posit potenti catalyst compani ahead
includ upgrad cycl around radixact synchroni
cyberknif volo product progress joint ventur china
chines licens grow us order funnel possibl
addit multi-unit order come look discuss topic
well step taken around annual cost reduct initi
model chang make chang model time
valuat rate neutral trade discount
mid-cap comp group use small cap due similar growth remain
neutral given lumpi order believ compani build
track record consist believ share begin see
meaning multipl expans compani must show depend
revenu order growth btig provid price target neutral-
rate stock risk includ order volum abil convert order revenu
system fall backlog potenti dilut product delay
ntm entm eepsrevsresmedrmdnot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
accuray incom product servic total y/i total cost gross sell gener total oper incom loss incom pre-tax incom incom net incom non-controlling net incom loss dilut share sbc other- adj marginsgross net mkting oper growthnananananananananananananananananananananananasourc btig estim compani report
accuray revenu egross y/i y/i y/i y/i y/i y/i y/i product servic total btig estim compani report
preview first quarter report public compani
expect clean earn report potenti small revenu beat
given see tight consensu rang achiev ramp first
three quarter also anticip may offer revenu
guidanc possibl may set forecast rang sale
estim revenu lp
compar consensu revenu revenu net
loss forecast line consensu believ dispar lp
estim function forecast share count assum less
half share novemb ipo impact dilut share
outstand quarter expect investor pay attent
revenu possibl oper expens model oper
expens line consensu spend much higher may
view neg given focu vapo rel high oper
forecast revenu oper expens
lp consensu look revenu
oper expens make public earn debut
expect guidanc given rel conserv perhap bracket
consensu estim first quarter estim revenu
oper expens lp consensu estim
revenu oper expens lp
beyond result hope hear compani salesforc expans
plan clinic educ digit market effort commentari flu
season util product pipelin
model chang make chang model time
valuat rate buy price target base
month revenu estim fast-grow med-tech comp
group trade multipl view revenu multipl appropri
balanc compani fast revenu growth rel high oper
expens lower gross margin devic compani risk includ
competit high oper expens price potenti ip challeng
single- sole-sourc raw materi compon
ntm inc ingnnot sciencesexasbuy medicalwmginot factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
vapotherm incom good gain fa oper expens incom tax expens incom prefer stock redempt gaap share net incom net incom analysisgross profit marginnanananananananananananapre-tax incomenananananananananananananet incom marginnanananananananananananaexpens revenu oper expensenanananananananananananay/i oper btig estim compani
vapotherm revenu erevenu us sale product per territori us revenu capit y/i unit precisionflow unit revenu y/i unit precisionflow unit us revenu y/i average precisionflow unit instal rate per precisionflow dispos circuit circuit revenu y/i average precisionflow unit instal rate per precisionflow dispos circuit circuit servic us revenu servic y/i average precisionflow unit instal revenu per precisionflow revenu servic y/i average precisionflow unit instal revenu per precisionflow precisionflow instal basebegin precisionflow unit instal precisionflow precisionflow unit instal precisionflow instal base everi precisionflow instal basebegin precisionflow unit instal precisionflow precisionflow unit instal precisionflow instal base everi btig estim compani
 buy tbd
preview januari compani pre-announc revenu
exceed forecast treatment revenu system
sale came forecast view trend encourag
remain confid compani abil drive y/i growth
back aggress salesforc expans grow clinician
awar share trade depress ntm sale estim
even solid quarter feel investor reward
approv reimburs japan would upsid estim
anoth catalyst
topic competit feel limit ip fragment market
complic stori neuronet closest competitor brainsway
bway rate file rais month part expand
commerci privat player like magstim privat also
sight amplifi reach said instal
base least size closest competitor
rel robust set clinic data larger infrastructur sens
competit environ chang market share seem mostli
besid guidanc would interest updat salesforc
hire plan look commentari dtc initi effort
model chang make chang model time
valuat neuronet rate buy tweak pt
compar multipl fallen also factor
delay japan approv increas competit nois least investor
mind new target multipl month sale estim
feel better reflect above-averag growth competit risk risk
includ competit chang reimburs intellectu properti fda
unsuccess salesforc effort contract healthcar multipl
ntm inc ingnnot exclud ntm ev-sal factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
neuronet incom etot y/i full year good expense/ incom per share analysisgross ratenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmgrowth analysisgross btig estim
neuronet revenu esystem builddbegin neurostar system add forecast sale neurostar system growth/ declin neurostar system rental neurostar system system y/i build quarterli activ activ instal activ treatment session volume/avg activ neurostar y/i treatment session volum y/i treatment session growth/ declin treatment session y/i y/i y/i y/i y/i btig estim
preview last month heliu execut coupl key
oper commerci goal includ secur fund ahead
anticip fda regulatori decis file ce mark applic
pon devic health canada clearanc start coupl new clinic
experi program cep total us
see coupl major catalyst ahead includ expect fda
regulatori decis pon devic start commerci patient
treatment canada expect submiss australian regulatori
applic look toward canadian sale weve model think
conserv two patient one patient two center convert
revenu may seem overli cautiou prefer take
rout patient willingness/ pay pocket turnaround
time hsdt receiv payment yet clear us though theoret
think strong demand therapi shown strong
efficaci worrisom side effect think busi model
canada allow heliu receiv revenu rel quickli await
commentari earli day canadian launch revisit
expect us fda decis continu see high likelihood
clearanc weve previous estim chanc ye due safeti
profil technolog efficaci data lack good option
patient popul continu hold us commerci sale
sinc assum cep program enrol clinic non-revenu
patient month post-clear
think hsdt share perform around earn may depend tone
commentari around canadian commerci us regulatori
outlook and/or pipelin
model chang make chang model time
valuat hsdt rate buy pt valuat base
dcf use discount rate use termin ev/ebit multipl
microcap comp group estim chanc fda
clearanc regulatori pathway never guarante see
low-risk profil technolog offset messi data
risk includ delay regulatori timelin regulatori clearanc
interpret data futur capit requir commerci execut
adopt ramp us reimburs single-product compani
heliu medic incom revenue- gross profit- research total oper expens incom pre-tax incom tax benefit net incom fx translat comprehens incom profit incom tax net oper btig estim compani report
heliu medic enu pon devic pon devic marketcumul center offer pon number patient adds/cent devic devic price devic enu marketcumul center offer pon number patient adds/cent devic devic price devic enu pon devic devic pon devic btig estim compani report
buy pt tbd
preview listen close electrocor earn call
indic reimburs coverag like roll throughout
model total revenu line consensu weve
model revenue-gener gammacor prescript
quarter number believ achiev light report
patient/prescrib demand off-set limit reimburs coverag
repres total gammacor prescript volum
prescript electrocor manag highlight januari
investor present metric miss estim though
admittedli guess base octob trend
script written octob alon would expect stronger ramp
end-of-year holiday still good sign refil
quarter higher anticip
look ahead see wide rang revenu estim
street view point uncertainti around reimburs
time competit forc determin quickli
enthusiasm technolog convert revenu recent gain
highlight compani reach earli target million cover live
may lead higher convert rate unclear quickli agreement
contract turn payment day-to-day basi
similarli like peer uncertain refil rate new
patient start ramp face signific competit new drug
correspond patient support program offer await
clariti manag offer earn call factor
would surpris near-term volatil street estim around
issu
past month made signific progress
includ fda clearanc adjunct use prevent cluster headach
adult patient start premium ii migrain prevent trial
feder suppli schedul win bring gammacor million
patient addit sale team seem gain traction
continu feel exact revenu number matter less stage
commentari clear progress clariti also matter hope get
better understand prescript volum revenu ramp might
unfold
model chang make chang revenu ep
estim adjust gammacor prescript written
period reflect level discuss manag compani latest
valuat rate buy lower price target
valuat base dcf assum discount rate prior
termin ev/ebit multipl use discount rate
reflect uncertainti around insur time lack clariti around
achiev revenu level head near term think share
trade quarterli report announc payor contract risk
futur capit need single-product compani
electrocor incom gross research total oper expens incom pre-tax incom tax benefit net incom net loss attribut non-controlling comprehens incom profit incom tax net oper btig estim compani report
electrocor revenu marketrevenue-gener patient patient prescript written rev-gener start rx convert price per refil deduct net price per refil net revenu devic cost gammacor gammacor profit gammacor refil cost gammacor gammacor profit gammacor gammacor profit btig estim compani report
preview onvo model revenu lp vs
street lp compani provid quarterli
annual guidanc make sequenti trend tough predict overal
expect major surpris accompani print outsid updat
continu traction busi prudent use cash continu come
better estim though expect ramp ahead first
ind calendar
calendar may catalyst name includ updat
pursuit anoth orphan design calendar pre-
ind meet fda discuss trial design patient
second half calendar compani also plan initi toxic
studi support multipl indic includ antitrypsin defici
model chang updat estim reflect
temper y/i ramp may aggress
product servic forecast past model revenu
also tweak sg spend given encourag
trend first half assum ramp estim net
loss
valuat organovo rate buy pt base dcf
analysi believ near-term ramp occur slower
envis given chang focu toward diseas model away
toxicolog servic believ onvo long-term invest
multipl opportun market liver kidney tissu preclin
test billion use tissu drug
discoveri could lead royalti payment potenti market
therapeut tissu would lead signific upsid risk includ
restructur effort bear fruit complic sale channel buyer
will adopt new technolog futur need capit fda
expect sale ramp
marginnmnmnmnmnmnmnmnmnmsourc btig estim compani filingsnewold chang
onvo incom etot y/i sale oper incom incom tax expens incom share incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens btig estim compani report
onvo revenu eproduct servic modelnumb program per program servic project modelnumb per collabor project btig estim compani report
preview earlier month endologix manag team pre-announce
revenu beat anoth strong result follow revenu
beat maintain sale outlook least
compani revenu forecast also set
higher consensu estim time
think result provid guidanc help elgx regain
credibl investor manag conserv proactiv
address issu clinician investor instanc recent
decis limit use nellix europ clinic protocol follow
current instruct use seem drastic us first prevent futur
problem lead pipelin product materi impact
revenu outlook type move like keep elgx less riski
forecast sale lp adj
lp street forecast sale lp
adj lp compani guid least revenu
expect key topic earn call includ salesforc retent
potenti attrit continu top concern evolut
compani balanc sheet might address debt clinic
pipelin timelin expect major chang around earn
report discuss
model chang make chang model time plan
updat pre-announce full earn releas
valuat endologix rate buy pt base
month revenu estim multipl slower-grow
small- mid-cap med-tech peer well group faster-
grow small cap compani one elgx could becom
take time nellix trial play risk includ
salesforc attrit signific neg impact field safeti notic
product recal nellix never launch us slow significantli
europ competit turnov need capit
ntm medicalwmginot factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
elgx incom etot y/i sale clinic market opex acq oper incom incom tax incom net incom share net incom oper expens btig estim compani report
elgx revenu esal geographi unit y/i y/i south america mexico y/i y/i y/i product y/i clinic specialist unit y/i revenu per us rep y/i growth revenue per us rep y/i revenu per eu rep y/i growth revenue per ou rep y/i btig estim compani report
preview valerita guid revenu
rang set novemb think there high likelihood
compani achiev target forecast revenu --
sale line consensu year
quarter forecast assum y/i growth prescript flat
forecast non-gaap lp vs consensu lp
anticip guidanc earn call forecast
total revenu year nearli us model
ou sale underli total prescript growth rate
y/i revenu estim match consensu lp model
non-gaap lp differ consensu
weve model share count anticip warrant exercis
earn call look discuss growth rate total new
prescript price trend sale rep hire may also hear
compani progress improv gross margin win prefer statu
payor think vlrx grow rapidli execut
goal believ warrant may remain overhang stock price
near term
model chang make chang model time
valuat vlrx rate buy price target base
month revenu estim assum full share dilut view revenu
multipl conserv given compani strong revenu growth lack
regulatori clinic data risk mani compani grow
trade well revenu believ recent secondari
offer anoth avail warrant exercis remov
near-term financ overhang despit dilut make share
palat investor next quarter think vlrx share
trade around quarterli result updat sale penetr within
target territori meaning revenu contribut ou
distribut agreement longer term believ signific room
multipl expans compani continu execut high-touch
commerci strategi expand margin withstand upcom
competit risk includ dilut relat novemb offer
small stand-alone compani potenti competit commerci
execut futur capit need
ntm inc ingnnot diabetestndmnot medicalwmginot factset data btig estimatespr ptpricemarket cap bev/salescagrev/gross profit
vlrx incom good asset impair oper tax expens incom stock share net incom net incom analysisgross profit incom revenu oper oper btig estim compani report
vlrx revenu esal geographi unit y/i total patient prescript y/i v-go y/i asp y/i representativesunit per us sale rep growth revenue per us sale btig estim compani report
preview model revenu fairli in-lin consensu
updat model metric provid januari assum
new account sign loss bello privat moder
ou revenu anticip mani surpris print given
high level transpar provid manag recent month
manag yet provid initi outlook model flat
revenu assum contribut bello
middl east commentari new account expect
area focu compani updat account select
process fairli recent factor turnaround earli feel
compani need meet consensu quarter row re-establish
investor interest confid growth would help recent effort
manag lock financ reduc overhang sens
investor would prefer see inflect point quarterli revenu
step
call await updat new commerci strategi
helm compani new ceo plan navig roll-out
model chang make hand tweak model base metric
provid last investor call assum contribut
middl east addit trim gross margin
introduct navig system depress overal margin
valuat obalon rate buy pt base
price risk competit end-us price percept safeti risk econom
downturn legal risk fail capit rais dilut financ
marginnmnmnmnmnmnmnmnmnm btig research estim compani filingsnewold changentm factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
obln incom etot y/i sale oper incom incom tax expens incom share oper expens btig estim compani report
obln revenu eu total total y/i y/i new sold balloons sale rep new order btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
